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Abstract
OBJECTIVE—To determine whether variation in the transcription factor 7-like 2 (TCF7L2) gene,
which influences diabetes risk, is associated with incidence of cancers.
RESEARCH DESIGN AND METHODS—We related diabetes and TCF7L2 variation with
occurrence of several common cancers in a prospective cohort study of 13,117 middle-aged adults
initially free of cancer in 1987–89. We assessed five SNPs in TCF7L2 including the putative SNP
(rs7903146) for diabetes. We identified incident cancers through 2000 via cancer registries,
supplemented by hospital records.
RESULTS—Diabetes was associated marginally inversely with incidence of prostate cancer, but
not associated with incidence of colorectal, colon, lung, or breast cancer. The T allele of rs7903146
(frequency = 30%) was associated with increased risk of colorectal cancer and, more specifically,
colon cancer, with adjusted hazard ratios (95% CI) of 1.0 for CC, 1.25 (0.85, 1.83) for CT, and 2.15
(1.27, 3.64) for TT genotypes (p for trend = 0.009). TCF7L2 variation also was associated with lung
cancer incidence in whites but not blacks, but residual confounding by smoking may be present.
CONCLUSIONS—Initially cancer-free subjects carrying certain genetic variants of TCF7L2, most
notably the T allele of rs7903146, have increased risk of colon cancer. This association appears to
be an independent gene effect, not explained by diabetes. Because the T allele of rs7903146 is
common, if a causal link is established, this variant could account for a sizable proportion
(approximately 17% here) of colon cancer cases in the general population.
Whether Type 2 diabetes is a cause of cancer is uncertain (1). Epidemiological studies have
often implicated diabetes as a risk factor for several cancers, including endometrial cancer
(1,2), pancreatic cancer (1,3), and colon cancer (1,4). However, often the classification of
diabetes in prior cancer studies has been based on self-reported diabetes, not measured fasting
glucose. Potential mechanisms connecting diabetes with increased cancer risk relate to obesity;
physical inactivity; diet; and increased insulin and insulin-like growth factor-1 (IGF-1).
Diabetes, on the other hand, may be associated with decreased risk of prostate cancer (5,6),
possibly because diabetic men tend to be hypoandrogenic (7,8). These epidemiological
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associations between diabetes and cancer, of course, might not be causal, but, rather, explained
by shared underlying causes of diabetes and cancer.
A number of studies have recently shown variation in the transcription factor 7-like 2
(TCF7L2) gene, previously called TCF-4, considerably affects risk of type 2 diabetes (9–12).
Although the mechanisms linking TCF7L2 variation with diabetes are still under investigation,
one study reported that the TCF7L2 risk variant, or its closest correlate, is the T allele of
rs7903146 (13). A meta analysis of over 17,000 diabetes cases reported that the T allele of
rs7903146 was associated with a relative risk of 1.46 (95% CI 1.42–1.51) for diabetes.
According to the concept of “Mendelian randomization (14),” if the T allele also were
associated with increased cancer risk, it would support a causal link between diabetes and
cancer. Alternatively, TCF7L2 may affect cancer independently of diabetes, as the TCF7L2
gene product is involved the Wnt/β-catenin signaling pathway. Mutations involving the Wnt
pathway and TCF target genes play a role in carcinogenesis, especially well documented for
colon cancer (15,16). Besides being expressed in the colon and colon cancer, TCF7L2 is
expressed in normal mammary gland and prostate tissue and in cancers of these tissues (17–
19) and non-small cell lung cancer (20).
We examined whether diabetes or variation in TCF7L2 is associated with incidence of four
common cancers – colorectal, prostate, female breast, and lung – in a large prospective cohort
study, the Atherosclerosis Risk in Communities (ARIC) Study. Because diabetes has been
associated epidemiologically more consistently with colorectal and prostate cancer than with
lung and breast cancer, we hypothesized that TCF7L2 variants increasing diabetes risk would
be associated positively with colorectal cancer and negatively prostate cancer incidence, but
unassociated with breast and lung cancer.
RESEARCH DESIGN AND METHODS
Population
ARIC is a cohort study of cardiovascular disease in four US communities. Between 1987 and
1989, 7,082 men and 8,710 women aged 45–64 years were recruited from Forsyth County,
North Carolina; Jackson, Mississippi (African Americans only); suburban Minneapolis,
Minnesota; and Washington County, Maryland. The ARIC Study protocol was approved by
the institutional review board of each participating university. After written informed consent
was obtained, participants underwent a baseline clinical examination (Visit 1). Follow-up
examinations of the cohort occurred three times, at intervals of roughly three years. The
response rates for Visits 2 (1990–1992), 3 (1993–1995), and 4 (1996–1998) were 93 percent,
86 percent, and 80 percent, respectively. Response to annual telephone interviews following
Visit 4 has been 94% of cohort survivors.
Risk factor measurements
Risk factors examined in these analyses were ascertained at Visit 1, as described in detail in
the ARIC Study manuals of operation (21). Participants were asked to fast prior to the clinical
examination. Blood was drawn from an antecubital vein of seated participants into vacuum
tubes containing ethylenediaminetetraacetic acid (for measurement of lipids and DNA
extraction) or a serum separator gel (glucose). Aliquots were stored at −70°C and were shipped
to central laboratories for analyses. Serum glucose was assayed by a hexokinase/glucose-6-
phosphate dehydrogenase method. Prevalent diabetes mellitus was defined as a fasting glucose
≥ 126 mg/dl (22), a self-reported physician diagnosis of diabetes, or current treatment for
diabetes.
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Body mass index was assessed with the subject wearing a scrub suit and no shoes.
Questionnaires assessed education, smoking status, number of cigarettes smoked per day and
duration of smoking (pack years computed), usual alcohol consumption (grams per day). Level
of sports physical activity was assessed by the Baecke Questionnaire (23).
ARIC genotyped five TCF7L2 SNPs, initially reported to be associated with diabetes (9)
(rs7903146, rs12255372, rs7901695, rs11196205, and rs7895340), on stored DNA using the
TaqMan system (Applied Biosystems, Foster City, CA). PCR primers and assay probes are
available from the authors upon request.
Cancer ascertainment
During each clinical examination, participants were asked whether they had ever been
diagnosed with cancer. At each annual telephone interview, participants reported all
hospitalizations. Among those not reporting cancer at the baseline visit, incident cancers were
identified between January 1, 1987, and December 31, 2000, via linkage to state cancer
registries and supplemented by the hospital records. This method and the high completeness
of ARIC cancer ascertainment were previously described (6,24). For this analysis, we focused
primarily on four site-specific common cancers (i.e., colorectal, lung, female breast, and
prostate).
Data analysis and statistical methods
From the original ARIC cohort (n = 15,792), we excluded participants who did not want to
participate in cancer research (n = 187), who denied permission for DNA testing (n = 79), who
were in very small race/ethnic minority groups (n = 96), who did not provide sufficient data
to determine baseline cancer status or who had a previous history of cancer (n = 877), who had
missing DNA or TCF7L2 genotypes (n = 927), or who had not fasted 8 hours (n = 509). This
left 13,117 in the cohort at risk.
Statistical analysis was performed by using SAS software (v. 9.1; SAS Institute, Inc., Cary,
North Carolina). Based on previous reports on diabetes and cancer (1,4–6), we hypothesized
that diabetes and TCF7L2 variation would relate to colorectal and prostate cancer incidence,
but not with breast and lung cancer. Person-years at risk were calculated from the time of
baseline clinical examination until the date of cancer diagnosis, death, loss to follow-up, or
December 31, 2000, whichever occurred first. To explore possible confounding factors, means
or prevalences of various risk factors were compared by TCF7L2 genotype, using t-tests or
chi-squared tests. Crude cancer incidence rates (per 1000 person-years) for TCF7L2 genotypes
were calculated. Adjusted hazard ratios (HRs) for the associations of the TCF7L2 variants and
diabetes with cancer incidence were calculated by using Cox proportional hazards regression.
The test for trend in HRs modeled 0, 1, or 2 risk alleles present. We tested for race by genotype
interactions; with the exception of lung cancer, none was significant, so for other cancers we
pooled blacks and whites. The proportional hazards assumption of the Cox model was found
not to be violated by testing an interaction between TCF7L2 variants and time. Our results
focus primarily on SNP rs7903146, which is believed to be the functional SNP for diabetes or
the closest correlate, but comment in the text about associations in secondary analyses of the
other four SNPs with cancer.
RESULTS
There were 433 incident cancers in 38,066 person-years of follow-up in blacks and 1274 in
109,701 person-years in whites, yielding crude incidence rates of cancer per 1000 person-years
of 11.4 in blacks and 11.6 in whites. As reported previously (6), in ARIC, baseline diabetes
was associated inversely with prostate cancer incidence (HR = 0.71, 95% CI 0.49, 1.03),
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although at p = 0.08 for this somewhat smaller sample with genotype data (Table 1). Diabetes
showed no significant association with colorectal, colon, breast, or lung cancer. Because
diabetes developed in many participants during follow-up, we repeated the analysis for Table
1 but modeling diabetes as a time dependent covariate. The results (not shown) were similar.
The race-specific frequencies of the five TCF7L2 SNPs, which are available upon request,
were in Hardy-Weinberg equilibrium. For rs7903146, the frequencies of CC, CT, and TT
genotypes were 50%, 42%, and 8% in whites and 50%, 41%, and 9% in blacks. Linkage
disequilibrium (r2) between rs7903146 and the other four TCF7L2 SNPs ranged from 0.44 to
0.97 in whites and 0.02 to 0.49 in blacks.
Associations of various risk factors with TCF7L2 rs7903146 are shown in Table 2. As expected,
diabetes prevalence showed a dose-response relation with the number of T-alleles present. The
number of T alleles was inversely related to BMI, as reported by others (25), and was positively
related to smoking. No other risk factor was associated strongly with rs7903146 variation. The
associations depicted in Table 2 were similar for whites and blacks.
As shown in Table 3, colorectal cancer was associated positively with the number of T alleles
for rs7903146, with multivariable-adjusted HRs of 1.17 (95% CI 0.85, 1.61) for CT and 1.56
(95% CI 0.97, 2.53) for TT, compared with CC. The number of rectal cancers was small, and
the association for colon cancer alone was even stronger: HR = 1.25 (95% CI 0.85, 1.83) for
CT and 2.15 (95% CI 1.27, 3.64) for TT compared with CC. These HRs were 1.19 and 2.01,
respectively, in whites and 1.46 and 2.69 in blacks. The association with colon cancer largely
persisted after adjusting for diabetes (not shown), or after excluding participants with baseline
diabetes: respective HRs were 1.32 for CT and 1.75 for TT (p for trend = 0.05). When analyzed
according to any regular use of aspirin during follow-up (assessed in 1994–95 in 12,138
subjects), the multivariably-adjusted HRs for colon cancer were similar among the 29% of
subjects who had regularly used aspirin (1.23 for CT and 2.21 for TT) and among the nonusers
(1.36 for CT and 2.21 for TT).
Lung cancer showed a significant positive association with the rs7903146 T allele in whites
but not blacks (Table 3). Breast and prostate cancers were not related to rs7903146T.
Associations between cancer and the other four TCF7L2 SNPs are not presented but are
available on request. Colon cancer incidence was associated positively, but more weakly (p
for trends = 0.04–0.14), with the other four TCF7L2 SNPs. Lung cancer in whites was
associated (p for trend <0.05) with variants in three of the five SNPs. Breast and prostate cancers
were not related to any TCF7L2 SNPs.
CONCLUSIONS
Our main new finding was that variation in TCF7L2 SNPs, particularly rs7903146, was
moderately strongly associated with incidence of colon cancer in this cohort. The incidence
rate of colon cancer was double in homozygotes for the T allele of rs7903146 compared with
the CC homozygotes. There was a dose response of colon cancer incidence with the number
of T alleles of rs7903146, and HRs were similar in blacks and whites. Some TCF7L2 SNPs
were also associated with lung cancer in whites, but not in blacks. Although TCF7L2 is a gene
that affects risk of type 2 diabetes (9,13), diabetes was associated with no cancer examined,
except inversely with prostate cancer, and the TCF7L2 association with colon cancer was
present when restricted to nondiabetic participants. Thus, the relation of TCF7L2 variation with
colon cancer appears to be an independent gene effect not explained by diabetes. Another study
has reported that the T allele of rs7903146 is associated with increased colon cancer incidence,
but only among non-users of aspirin (26). We did not observe such effect-modification by
aspirin.
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The rs7903146 SNP resides within intron 3 in a 50K base pair region of the TCF7L2 gene.
Currently, the function of rs7903146 is unknown but is under investigation. Certainly, it may
be another mutation in LD with this SNP that affects gene function. In any case, a causal link
between TCF7L2 variation and colon cancer seems biologically plausible. This gene has a
central role in the Wnt/β-catenin signaling pathway, which is strongly implicated in colon
cancer etiology (15,16). Mutations in the adenomatous polyposis coli (APC) gene cause colon
cancer via this pathway. APC normally functions as a negative regulator of Wnt signaling by
the destabilization of the β-catenin protein. Stabilized β-catenin interacts with TCF7L2 and
LEF to activate gene expression. Mutations in either APC or genes that modulate β-catenin
can alter this regulatory relationship and lead to the activation or inhibition of genes that
contribute to neoplasia (26). Although we had too few rectal cancer cases to analyze separately,
the association with TCF7L2 rs7903146 seemed more specific for colon cancer alone than for
grouped colorectal cancer. Further replication of our finding, including epidemiologic studies
of TCF7L2 and colon adenomas, seems warranted. If the relation were causal, the estimated
population risk of colon cancer attributable (27) to rs7903146 is 17%, given the genotype
frequencies and hazard ratios observed here.
The association between TCF7L2 variation and lung cancer in whites was unexpected, because
smoking is clearly the overwhelming cause of lung cancer. Although the Wnt/β-catenin
pathway may be involved in lung cancer, this has only limited documentation (20). Also
unexpected was the association in ARIC between TCF7L2 rs7903146 and smoking status and
pack-years. To our knowledge, no previous study has reported this association, so it may be a
chance or spurious finding. We adjusted the association between TCF7L2 and lung cancer for
smoking variables, but it is possible that there is residual confounding by smoking. Given that
an association of TCF7L2 with lung cancer was not hypothesized and found only in whites,
this finding should be viewed cautiously.
Strengths of this study were the prospective design and highly complete ascertainment of
cancer. The main limitations were the moderate number of cancer events and absence of detail
(e.g., histologic review, stage, biomarkers such as prostate-specific antigen) on them. Further,
candidate gene studies often yield false positive results. Thus, even though the associations we
identified seem biologically plausible, they need replication.
In conclusion, initially cancer-free subjects carrying certain common genetic variants of
TCF7L2, most notably the T allele of rs7903146, have increased risk of colon cancer. This
association appears to be an independent gene effect, not explained by diabetes. Because the
T allele of rs7903146 is common, if a causal link is established, this variant could account for
a significant proportion of colon cancer cases in the general population.
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Table 2










  Diabetes (%) 9.0 11.9* 13.7*
  Current smoking (%) 24.6 26.0 27.9*
  High school graduate (%) 77.7 75.2* 76.8
  Current HRT use (women) (%) 23.3 22.0 20.9
Means
  BMI (kg/m2) 27.8 27.6* 27.5*
  Pack years of smoking 309 317 336*
  Ethanol intake (g/week) 42.1 42.3 42.9
  Sport Activity Index (range: 1–5) 2.44 2.44 2.42
*
p<0.05 compared with CC
ARIC = Atherosclerosis Risk in Communities Study
BMI = Body Mass Index
HRT = Hormone Replacement Therapy
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